1 / 25

LUNG TRANSPLANTATION and PULMONARY FIBROSIS

LUNG TRANSPLANTATION and PULMONARY FIBROSIS. Maria L. Padilla, MD Associate Prof. of Medicine Director of ILD/IPF and Advanced Lung Disease Program MSSM/MSMC. Organ Transplantation. Lung Transplantation and IPF. Important Questions: What is it? Why? For Whom? When? How?

jill
Download Presentation

LUNG TRANSPLANTATION and PULMONARY FIBROSIS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. LUNG TRANSPLANTATION and PULMONARY FIBROSIS Maria L. Padilla, MD Associate Prof. of Medicine Director of ILD/IPF and Advanced Lung Disease Program MSSM/MSMC

  2. Organ Transplantation

  3. Lung Transplantation and IPF • Important Questions: • What is it? • Why? • For Whom? • When? • How? • What are the results?

  4. Lung Transplantation and IPF • What is Lung Transplantation? The operation that replaces diseased, failing lungs with a functional organ.

  5. Lung Transplantation and IPF • Thoracic Transplantation • Heart-Lung Transplantation • Single Lung Transplantation • Bilateral Lung Transplantation • Lobar Transplantation

  6. Lung Transplantation and IPF • WHY? It offers the opportunity to return to a better functional capacity when all medical therapies have been ineffective. Ultimate form of treatment

  7. Lung Transplantation • Process: • Referral • Evaluation • Listing with UNOS • Waiting time • Transplantation • Post transplantation care

  8. Lung Transplantation and IPF • For whom? • Candidate Selection • Age less than 65y • Absence of other organ dysfunction • Non-smoker, non-drinker, no drug abuse • Appropriate weight • Good support system • Stable psychosocial and emotional status

  9. Lung Transplantation • CANDIDATE EVALUATION • Blood type, biochemical panel, serologies • Renal function determination • Skin testing and sputum cultures • PFT’s , ABG’s, 6-min walk, +/-exercise tests • Imaging: CXR, HRCT, V/Q, bone densitometry • Cardiac tests: echo; stress tests; RHC with hemodynamics and LHC where indicated

  10. Lung Transplantation and IPF • When? When patient is: medically physically psychologically/emotionally, READY! and lungs become available

  11. Lung Transplantation • LESS THAN 20% OF DONORS ARE SUITABLE LUNG DONORS: • AGE AND SMOKING HX EXCLUDE SOME • LUNGS ARE FRAGILE--EDEMA, INFXN, VENTILATOR COMPLICATIONS • ALLOGRAFT INTOLERANCE TO PROLONGED ISCHEMIA

  12. Lung Transplantation and IPF • When lungs become available, they are offered on the basis of: • Time on the waiting list • No consideration for severity of illness or urgency • Exception: 90 d credit when IPF patient listed • Blood type • Lung size • Other factors (?)

  13. Lung Transplantation and IPF • While on Waiting List: • Adhere to medical treatment • Participate in pulmonary rehabilitation • Maintain good nutrition and acceptable body weight • Attend support groups • Keep a positive attitude and visualize a brighter tomorrow

  14. Lung Transplantation • Registry: • United Network for Organ Sharing and the Organ Procurement and Transplantation Network (UNOS/OPTN) • 1988-2000 • 7764 lung transplants (7625 C, 139 LD) • 719 heart-lung transplants • Data as of Nov. 2000

  15. Lung Transplantation

  16. Lung Transplantation and ILD • Activity (SLT and BLT)- 1988-1999 • IPF (LD 5) 972 • SARCOIDOSIS 148 • PF (OTHER) 82 • LAM 47 • OB (non-retransplant) 46 • OCCUP. LUNG DIS. 11 • RHEUMATOID DIS. 5 • From UNOS/OPTN data as of 2/17/2001

  17. Lung Transplantation and IPF • Idiopathic Pulmonary Fibrosis • Waiting time too long for some patients • At risk for developing 2* PHN • Prior Thoracic surgeries (OLB, Ptx) • High frequency of osteoporosis, obesity • Documented survival benefit • H-L, 2.9%; BLT, 7.1%; SL, 19.5% (ISHLT)

  18. Lung Transplantation-IPF

  19. Lung Transplantation-IPF

  20. Lung Transplantation • Issues and complicating factors • Need for chronic immunosuppression • Acute and chronic rejection • Infection • Side effects of medicines • Cost of procedure and follow up care

  21. Lung Transplantation and ILD • IMPROVED FUNCTIONAL STATUS • IMPROVED PHYSIOLOGY(pulm+ cv) • SURVIVAL BENEFIT (IPF) • COMPARABLE INCIDENCE OF AR, CR INFECTION • IMPROVED QUALITY OF LIFE

  22. Lung Transplantation

  23. Lung Transplantation

  24. Lung Transplantation

  25. Lung Transplantation and IPF/ILD • LT is a therapeutic modality of great value • Efforts to overcome LT limitations needed: • Increase donor pool--review criteria • Living donors---Lobar transplantation • Prevent CR-improve treatment • Earlier listing of candidates with ILD/IPF • Explore new therapies as bridge to LT • New IPF paradigm

More Related